Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06016088 · ClinicalTrials.gov registry record · Phase 1

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

A Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung, sponsored by Respirion Pharmaceuticals Pty.

Recruiting
Registry status
Phase 1
Development phase
72
Enrollment target
20
Study locations

NCT06016088 is a Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung that is actively recruiting participants, run by Respirion Pharmaceuticals Pty. The registered enrollment target is 72 participants, below the 102-participant average among 4 other Pseudomonas Aeruginosa trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06016088, a Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung, is actively recruiting participants, sponsored by Respirion Pharmaceuticals Pty.

RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
20
Study locations

Study Summary

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.

Conditions Studied

Pseudomonas Aeruginosa Cystic Fibrosis Lung Respiratory Infections, Recurrent, Chronic

Interventions

  • DRUG RSP-1502
  • DRUG Tobramycin inhalation solution

Study Locations (20)

California

  • Center for Cystic Fibrosis at Keck Medical Center of USC - Los Angeles
  • Stanford University Medical Center - Palo Alto

Ohio

  • Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center - Cleveland
  • Nationwide Children's Hospital - Columbus

New South Wales

  • Royal Prince Albert Hospital - Camperdown
  • Westmead Hospital - Westmead

Queensland

  • Queensland Children's Hospital - Brisbane
  • The Prince Charles Hospital - Brisbane

Victoria

  • The Alfred Hospital - Melbourne
  • The Royal Children's Hospital - Parkville

Arizona

  • Tucson Cystic Fibrosis Center - Tucson

Georgia

  • Augusta University - Augusta

Illinois

  • The Cystic Fibrosis Institute - Northfield

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2024-04-01
Est. Completion 2026-06
Phase Phase 1

Sponsor

Respirion Pharmaceuticals Pty

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06016088

The ClinicalTrials.gov registry entry for NCT06016088 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 4 other Pseudomonas Aeruginosa trials with a reported enrollment target (29% lower). The listed sponsor is Respirion Pharmaceuticals Pty, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pseudomonas Aeruginosa appearing as the primary indexed condition, and to 2 interventions - of which RSP-1502 is the first listed.

NCT06016088 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Ohio, New South Wales.

Frequently Asked Questions

What is clinical trial NCT06016088 about?

NCT06016088 is a clinical study titled "A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection". A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.

What is the current status of trial NCT06016088?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-04-01. Estimated completion is 2026-06.

What conditions does trial NCT06016088 study?

This clinical trial studies the following conditions: Pseudomonas Aeruginosa, Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic.

What interventions are being tested in trial NCT06016088?

The interventions under investigation include: RSP-1502 (DRUG), Tobramycin inhalation solution (DRUG).

Who is sponsoring clinical trial NCT06016088?

This trial is sponsored by Respirion Pharmaceuticals Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06016088 being conducted?

This trial has 20 study locations across Arizona, California, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pseudomonas Aeruginosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pseudomonas Aeruginosa

All registered trials for this condition

Cystic Fibrosis Lung

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.